Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 0.70 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884962 | 1.00 | CCR3 (0.70) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3885468 | 0.90 | CCR3 (0.57) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3881284 | 0.90 | CCR3 (0.57) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3881197 | 0.89 | CCR3 (0.57) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3881565 | 0.89 | CCR3 (0.57) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3881200 | 0.89 | CCR3 (0.57) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3886783 | 0.87 | CCR3 (0.70) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3886781 | 0.87 | CCR3 (0.70) | CCR3HTR2ACYP2D6DRD2SLC6A2 | |
| SCHEMBL3877837 | 0.85 | CCR3 (0.57) | CCR3CYP2D6 | |
| SCHEMBL3881845 | 0.85 | CCR3 (0.57) | CCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | claimed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | claimed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | claimed |
| WO-2003024401-A2 | PIPERIZINONES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | claimed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | disclosed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CCR3 1/4885HTR2A 2713/4885CYP2D6 2646/4885 |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CCR3 1/4885HTR2A 2683/4885CYP2D6 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.